

AstraZeneca India
Symposium on Tuberculosis Research – An Indian Perspective
(TRIP)
20 October 2005

Programme

Session I - 9:00 – 12:30	
9:00 - 9:10	Chairperson : Dr. R.K. Shandil , AstraZeneca R&D Bangalore
9:10 – 9:45	<i>In silico</i> identification of novel biosynthetic pathways in <i>Mycobacteria</i> Dr. D. Mohanty Staff Scientist, National Institute of Immunology, New Delhi
9:45 – 10:20	Structure-function studies on enzymes involved in the complex lipid cell wall biosynthesis of <i>Mycobacterium tuberculosis</i> Dr. R. Sankaranarayanan Scientist E1, Centre for Cellular and Molecular Biology, Hyderabad
10:20 – 10:55	Structural studies reveal interesting unusual properties of proteins in <i>Mycobacterium tuberculosis</i> . Dr. Shekhar C. Mande Head, Laboratory of Structural Biology, Centre for DNA Fingerprinting & Diagnostics, Hyderabad
10:55 – 11:15	Refreshments Break
11:15 – 11:50	Validation of <i>Mycobacterium tuberculosis</i> genes as Drug Targets Dr. A.K. Tyagi Head, Department of Biochemistry, University of Delhi South Campus, New Delhi
11:50 – 12:25	<i>Mycobacterium tuberculosis</i> : Convergence of Molecular epidemiology and drug discovery efforts Dr. S.E. Hasnain Director, Centre for DNA Fingerprinting & Diagnostics, Hyderabad
12:25 – 13:30	Lunch Break

Each talk will be of 25 minutes duration including 10 for discussion

AstraZeneca India
Symposium on Tuberculosis Research – An Indian Perspective
(TRIP)
20 October 2005

Continued.... 2

	Session II - 13:30 – 17:45
13:30 – 13:40	Chairperson : Dr. Meenakshi Balganesh , AstraZeneca R&D Bangalore
13:40 – 14:15	Insight into how mycobacterial effectors modulate the macrophage innate immune response Dr. Joyoti Basu Reader, Department of Chemistry, Bose Institute Kolkata
14:15 – 14:50	Modulation of Macrophage Immune Functions By A Mycobacterial Secretory Antigenic Protein, MTSA-10 Dr. Pawan Shrama Senior Research Scientist , ICGEB - International Centre for Genetic Engineering and Biotechnology, New Delhi
14:50 – 15:25	Shortening TB treatment - five decades of clinical trials at TRC Dr. M.S. Jawahar Deputy Director (Sr. Gr.), Clinic Division, Tuberculosis Research Centre, Chennai.
15:25 – 15:45	Refreshments break
15:45 – 16:20	MDR-TB an India perspective Dr. Z.F. Udawadia Infectious Diseases Specialist, PD Hinduja National Hospital & Medical Research Centre, Mumbai
	Session III: Drug Hunting Perspectives for TB
16:20 – 16:50	Dr. Les Hughes VP and Head of Discovery Cancer & Infection, AstraZeneca Pharmaceuticals, UK
16:50 – 17:35	An Endocrinologists Perspectives on Tuberculosis Dr. Barry Furr Chief Scientist, AstraZeneca India Pvt. Ltd. Bangalore
17:35 – 17:45	Closing Remarks Dr. T.S. Balganesh

Each talk will be of 25 minutes duration including 10 for discussion